Dr Rani Khatib FESC

🧵 The first short publication about my COVID-19 battle is out. "My near-death experience with COVID-19: Learning lessons as a healthcare professional" In the @JCardFail Thank you @ShelleyZieroth so much for the opportunity. doi.org/10.1016/j.card…

Artificial intelligence in cardiovascular pharmacotherapy: applications and perspectives. A State-of-the-Art review just in #EHJ 👉ow.ly/SUZw50WrMEv @RoccoMontone @ehj_ed #AI

My latest @Medscape Medical Mentor podcast is live! 🔶What is Lp(a), and when should we check it?🔶 🎯Lp(a) is an important but underappreciated independent risk factor for #ASCVD Link in comments👇🏾 Also on @Spotify & @ApplePodcasts

Reasons for non-adherence among patients with IHD. openheart.bmj.com/content/6/2/e0…

COVID-19 never stops having consequences. Avascular necrosis! casereports.bmj.com/content/14/7/e…

✅️ shift from treating CKD to preventing across lifespan - start early + use MDTs. ✅️ Modifiable risks: T2DM, HTN, obesity, dyslipidemia ✅️ Use Screening & Risk Tools ✅️ Lifestyle & Environment changes ✅️ SGLT2i, GLP-1RA, Tirzepatide, Finerenone kdigo.org/conferences/co…

Are you a healthcare professional based in the UK? Are you part of a Cardiovascular Renal Metabolic Service? If yes, please help us by completing this survey (UK only): Exploring the Cardio-Renal-Metabolic Services in the UK app.onlinesurveys.jisc.ac.uk/s/leeds/cardio…

Join our @NHSEngland webinar on: "Revolutionising CVD Prevention - Lipid Lowering Management via Innovative Approaches" on the 11th Aug. Please register here: events.england.nhs.uk/events/cvd-pre…

Growing evidence showing the benefits of simultaneous initiation of SGLT2i and Finerenone in CKD with T2D. UACR ⬇️ at day 180: 52% with combination. Observed within 2 weeks and plateaued by 3 months. SBP dropped more significantly with combination therapy (7.4 mmHg decrease).

Heart failure with preserved ejection fraction therapeutics: in search of the pillars transformative era in HFpEF management, with multiple landmark clinical trials demonstrating benefits for novel therapeutic classes : SGLT2i , Ns-MRAs, GLP-1a link.springer.com/article/10.100…

Colleagues, yes DNAs are frustrating & cost the NHS money. However, please be kind & avoid being judgmental when sending DNA letters. In many instances the cause of the DNA are faults in our system or miscommunications. Not all DNAs are due to people not being bothered.

Optimization of RAASi therapies for evidence-based indications: a call to action from the cardio-kidney community 🫀 RAASi essential for treating diabetic and non-diabetic #CKD, #heartfailure & #HTN 🫀 guidance for optimizing RAASi therapy #CVPrev 📎 shorturl.at/EXzUk

Excellent session on "Optimising meds for people living with CVD" at @escardio ACNAP Congress 2025. 🔴 Polypharmacy & CVD 🔴 Simulated practice discharge advice for nurses supporting CVD patients 🔴 Meds data visualisation tool supporting CVD patients #ACNAP2025

At our recent session at @escardio ACNAP Congress 2025 we discussed the pharmacological management of obesity. #ACNAP2025

Lipid optimisation and managing statin intolerance youtube.com/watch?v=NALw5t…

Supporting appropriate use of extended dual antiplatelet therapy post-myocardial infarction based on an innovative 12-month ticagrelor virtual service. frontiersin.org/journals/cardi…

#ACNAP2025 session Obesity in CV disease very informative and useful session! 🎯activity increase not just diet 🎯one diet does not fit all 🎯GLP 1 muscle loss with weight loss 🎯we need to avoid assumptions in overweight patients @DrRaniKhatib @Ir_Gibson and Michał Czapla👏

📌Your language matters: avoid judgemental words 📌 Reflect on your own bias and avoid making assumptions 📌Use the 5As of obesity management @Ir_Gibson @DrRaniKhatib @drczapla #ACNAP2025